On standalone basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Supriya Lifescience has increased 32.54% to Rs 185.65 crore. Operating profit margin has jumped from 29.61% to 35.52%, leading to 58.99% rise in operating profit to Rs 65.95 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 34.42% to 9.89%. Employee cost increased from 13.48% to 14.38%. Other expenses rose from 20.27% to 27.75%. Other income fell 31.60% to Rs 2.1 crore. PBIDT rose 52.75% to Rs 68.05 crore. Provision for interest up 4.08% to Rs 0.51 crore. PBDT rose 53.29% to Rs 67.54 crore. Provision for depreciation rose 25.25% to Rs 4.96 crore. Profit before tax grew 56.06% to Rs 62.58 crore. Provision for tax was expense of Rs 15.8 crore, compared to Rs 10.31 crore. Effective tax rate was 25.25% compared to 25.71%. Profit after tax rose 57.03% to Rs 46.78 crore. Promoters’ stake was 68.30% as of 31 December 2024 ,compared to 68.30% as of 31 December 2023 .
For year-to-date (YTD) results analysis
Net sales (including other operating income) of Supriya Lifescience has increased 24.31% to Rs 512.38 crore. Operating profit margin has jumped from 28.50% to 37.71%, leading to 64.48% rise in operating profit to Rs 193.21 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 36.52% to 26.88%. Employee cost decreased from 12.89% to 12.23%. Other expenses rose from 20.61% to 21.21%. Other income fell 19.05% to Rs 6.84 crore. PBIDT rose 58.87% to Rs 200.05 crore. Provision for interest fell 15.89% to Rs 1.27 crore. PBDT rose 59.78% to Rs 198.78 crore. Provision for depreciation rose 20.67% to Rs 14.36 crore. Profit before tax grew 63.91% to Rs 184.42 crore. Provision for tax was expense of Rs 46.84 crore, compared to Rs 30.33 crore. Effective tax rate was 25.40% compared to 26.96%.Profit after tax rose 67.41% to Rs 137.58 crore. Promoters’ stake was 68.30% as of 31 December 2024 ,compared to 68.30% as of 31 December 2023 .
Full year results analysis
Net sales (including other operating income) of Supriya Lifescience has increased 23.74% to Rs 570.37 crore. Operating profit margin has jumped from 27.96% to 30.33%, leading to 34.19% rise in operating profit to Rs 172.97 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 40.07% to 35.45%. Employee cost increased from 11.89% to 12.52%. Other expenses fell from 20.46% to 20.00%. Other income up 12.12% to Rs 10.64 crore. PBIDT rose 32.68% to Rs 183.61 crore. Provision for interest fell 31.49% to Rs 2.11 crore. Loan funds declined from Rs 22.47 crore as of 31 March 2023 to Rs 5.49 crore as of 31 March 2024. Inventories declined from Rs 115.77 crore as of 31 March 2023 to Rs 85.25 crore as of 31 March 2024. Sundry debtors were higher at Rs 111.68 crore as of 31 March 2024 compared to Rs 84.66 crore as of 31 March 2023. Cash and bank balance declined from Rs 157.58 crore as of 31 March 2023 to Rs 74.96 crore as of 31 March 2024. Investments rose to Rs 63.80 crore as of 31 March 2024 from Rs 25.30 crore as of 31 March 2023 . PBDT rose 34.14% to Rs 181.5 crore. Provision for depreciation rose 33.76% to Rs 15.81 crore. Fixed assets increased to Rs 457.30 crore as of 31 March 2024 from Rs 328.06 crore as of 31 March 2023. Intangible assets increased from Rs 1.11 crore to Rs 1.66 crore. Profit before tax grew 34.17% to Rs 165.69 crore. Provision for tax was expense of Rs 46.58 crore, compared to Rs 33.63 crore. Effective tax rate was 28.11% compared to 27.23%. Profit after tax rose 32.55% to Rs 119.11 crore. Promoters’ stake was 68.30% as of 31 March 2024 ,compared to 68.28% as of 31 March 2023 . Cash flow from operating activities increased to Rs 113.31 crore for year ended March 2024 from Rs 63.61 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 145.66 crore, compared to Rs 107.91 crore during the year ended March 2023. Other Highlights
In
Q3 FY25, Asia contributed 31% to total revenue, Europe 40%, LAC 21%, North America
3% and others 5%.
During
9M FY25, Asia contributed 32% to total revenue, Europe 43%, LAC 17%, North America
4% and others 4%.
In
Q3 FY25, in terms of therapy wise contribution, Analgesic/Anesthetic
contributed 60% to revenue, Anti-histamine 12%, Vitamins 10%, Anti-Asthmatic
4%, Anti-allergic 4% and Anti-hypertensive 1%.
| Supriya Lifescience : Standalone Results | | Quarter ended | Year to Date | Year ended |
|---|
| Particulars | 202412 | 202312 | Var.(%) | 202412 | 202312 | Var.(%) | 202403 | 202303 | Var.(%) |
|---|
| Net Sales (including other operating income) | 185.65 | 140.07 | 32.54 | 512.38 | 412.19 | 24.31 | 570.37 | 460.94 | 23.74 | | OPM (%) | 35.52 | 29.61 | 591 bps | 37.71 | 28.50 | 921 bps | 30.33 | 27.96 | 236 bps | | OP | 65.95 | 41.48 | 58.99 | 193.21 | 117.47 | 64.48 | 172.97 | 128.90 | 34.19 | | Other Inc. | 2.10 | 3.07 | -31.60 | 6.84 | 8.45 | -19.05 | 10.64 | 9.49 | 12.12 | | PBIDT | 68.05 | 44.55 | 52.75 | 200.05 | 125.92 | 58.87 | 183.61 | 138.39 | 32.68 | | Interest | 0.51 | 0.49 | 4.08 | 1.27 | 1.51 | -15.89 | 2.11 | 3.08 | -31.49 | | PBDT | 67.54 | 44.06 | 53.29 | 198.78 | 124.41 | 59.78 | 181.50 | 135.31 | 34.14 | | Depreciation | 4.96 | 3.96 | 25.25 | 14.36 | 11.9 | 20.67 | 15.81 | 11.82 | 33.76 | | PBT | 62.58 | 40.10 | 56.06 | 184.42 | 112.51 | 63.91 | 165.69 | 123.49 | 34.17 | | PBT before EO | 62.58 | 40.1 | 56.06 | 184.42 | 112.51 | 63.91 | 165.69 | 123.49 | 34.17 | | EO Income | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | PBT after EO | 62.58 | 40.1 | 56.06 | 184.42 | 112.51 | 63.91 | 165.69 | 123.49 | 34.17 | | Taxation | 15.8 | 10.31 | 53.25 | 46.84 | 30.33 | 54.43 | 46.58 | 33.63 | 38.51 | | PAT | 46.78 | 29.79 | 57.03 | 137.58 | 82.18 | 67.41 | 119.11 | 89.86 | 32.55 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 46.78 | 29.79 | 57.03 | 137.58 | 82.18 | 67.41 | 119.11 | 89.86 | 32.55 | | EPS (Rs)* | 5.81 | 3.70 | 57.03 | 17.09 | 10.21 | 67.41 | 14.80 | 11.17 | 32.55 | | | * EPS is on current equity of Rs 16.10 crore, Face value of Rs 2, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|